Anne M. Schultheis - Concepedia

Author

Anne M. Schultheis

Also Known As

A M Schultheis, A Schultheis, A. M. Schultheis, A. Schultheis, A.M Schultheis, A.M. Schultheis, Anne M Schultheis, Anne M. Schultheis, Anne Maria Schultheis, Anne Schultheis

125

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

University Hospital Cologne Memorial Sloan Kettering Cancer Center University of Cologne Düsseldorf University Hospital University of Southern California

About

Anne M. Schultheis is an author at University Hospital Cologne specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	1.9K
2	Cell Biology	7	7	781
3	Health Sciences	2	2	105
4	Public Health	2	2	283
5	Engineering	1	1	30

Anne M. Schultheis

Publications

Citations

H-Index

Page 1

	Year	Citations
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab Wu Zhang, Michael A. Gordon, Anne M. Schultheis, Journal of Clinical Oncology	2007	478
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans Kellie A. Charles, Hagen Kulbe, Robin Soper, Journal of Clinical Investigation Cd4+ CellsImmunologyImmune RegulationImmunologic MechanismCd4 T Cell Responses	2009	333
Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas Anne M. Schultheis, Charlotte K.Y. Ng, Maria Rosaria De Filippo, JNCI Journal of the National Cancer Institute Parallel SequencingSynchronous Endometrioid EndometrialPathologyGynecologyFavorable Prognosis	2015	249
PD-L1 expression in small cell neuroendocrine carcinomas Anne M. Schultheis, Andreas H. Scheel, Luka Ozretić, European Journal of Cancer	2015	236
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups L. H. Schmidt, Andreas Kümmel, Dennis Görlich, PLoS ONE	2015	227
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer Anna Kron, Christina Alidousty, Matthias Scheffler, Annals of Oncology	2018	207
<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung Hans‐Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff, Clinical Cancer Research	2014	187
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab Anne M. Schultheis, Georg Lurje, Katrin E. Rhodes, Clinical Cancer Research	2008	184
<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas Lydia Meder, Katharina König, Luka Ozretić, International Journal of Cancer Cancer ResearchPrimary SclcRare Secondary SclcAlternative PathwayTumor Microenvironment	2015	174
Genomic landscape of adenoid cystic carcinoma of the breast Luciano G. Martelotto, Maria Rosaria De Filippo, Charlotte K.Y. Ng, The Journal of Pathology	2015	149

Page 1